RESUMEN
This research reports the unique case of manifestation of symptomatic dermographism which includes all of its twenty five members of the family. Probing a genetic transmission autosomal dominant manner and taking into account the highly probable role of HLA in this illness. The symptomatic dermographism correspond to a group of physical familiar urticarias with symptoms appearing in early childhood and evolving throughout adulthood with seldom periods of remission. Due to the fact that all patients were affected, it was not possible to realize a typification of HLA antigens with persons not affected, to establish a relationship with the data obtained. However, results show a significant association of haplotypes; HLA A2 (78.95), B16 (68.4%), A1 (47.3%), and B5 (42.5%) among the most important. This is the first research that reports the analysis of HLA within the physical familial urticarias.
Asunto(s)
Urticaria/inmunología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Antígenos HLA , Humanos , Masculino , Persona de Mediana Edad , Linaje , Urticaria/genéticaRESUMEN
Heparin is the anticoagulant used during cardiopulmonary bypass (CPB). Both the use of heparin and the reversal of its effect with protamine have well-documented complications. Ancrod is a defibrinogenating enzyme that has been used as an anticoagulant in humans, but its use as an anticoagulant for CPB has been limited to studies in animals. Twenty patients for elective aortocoronary bypass surgery were anticoagulated by means of an intravenous infusion of ancrod pre-operatively. Target plasma fibrinogen concentrations of 0.40-0.80 g/l were achieved within 13.3 +/- 2.5 h using an average dose of ancrod of 1.65 +/- 0.55 U/g. All perfusions were without incident. Postoperative blood loss (2286 +/- 1311 cc) was compared to that of 20 matched controls (1737 +/- 973 cc), as was blood product use; 4.1 +/- 2.1 U of packed cells versus 2.5 +/- 2.3 U (P less than 0.05) and 5.6 +/- 3.1 U of plasma versus 2.6 +/- 2.9 U (P less than 0.05) in the ancrod and heparin-treated groups, respectively. There were no differences in the postoperative courses or recovery periods of the ancrod-treated and control patients. This study confirms the efficacy and feasibility of ancrod as an alternative form of anticoagulation for CPB.